Figure 3.1 (A) Expression of different glutamate receptor subtypes, demonstrating the complexity expected in any attempt to modulate glutamatergic neurotransmission. (B) Illustration of the corticostriatal circuits, demonstrating the role of…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 32 Lessons and challenges of trials involving ancillary therapies for the management of Parkinson’s disease Chris J. Hass, Elizabeth L. Stegemöller, Madeleine E. Hackney and…
Figure 31.1 Therapeutic approach to the common nonmotor symptoms of Parkinson’s disease. Sialorrhea Drooling is present in 80% of patients with PD and is secondary to disturbances in swallowing the…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 30 Lessons and challenges of trials for cognitive and behavioral complications of Parkinson’s disease Daniel Weintraub and Lama M. Chahine Introduction There has been increasing…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 28 Controversy: ablative surgery vs deep-brain stimulation in the management of Parkinson’s disease Gian D. Pal and Leo Verhagen Metman Introduction The concept of surgically…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 29 Controversy: midstage vs advanced-stage deep-brain stimulation in the management of Parkinson’s disease Mallory L. Hacker and David Charles Introduction Parkinson’s disease (PD) is a…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 27 Controversy: globus pallidus internus versus subthalamic nucleus deep-brain stimulation in the management of Parkinson’s disease Sarah K. Bourne, Sean J. Nagel and Darlene A….
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 26 Lessons learned: symptomatic trials in early Parkinson’s disease Ramon Lugo-Sanchez and Néstor Gálvez-Jiménez Introduction This chapter will try to explain the concept of “early”…
Figure 25.1 Schematic representation of the theoretical effect of neuroprotective, symptomatic, or mixed neuroprotective and symptomatic treatments compared with placebo in different study designs. The x-axis represents time and the…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 23 Functional imaging markers as outcome measures in clinical trials for Parkinson’s disease Ryan R. Walsh Introduction There is currently no validated functional imaging marker…
